Nan Fung Group Holdings Ltd
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Nan Fung Group Holdings Ltd reported 35 stock positions worth $116.9 million. Its top holding was Illumina (ILMN) at 13.6% of the portfolio, followed by Harmony Biosciences (HRMY, 10.8%) and Oculis (OCS, 6.3%). Compared with Q3 2024, it opened 3 new positions, sold out of 6, added to 8 and reduced 2. The biggest buy was a new position in Verona Pharma (VRNA) and the biggest sale an exit from Longboard Pharmaceuticals (LBPH).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $116.9M (Q4 2024)
- SEC Filing
- 0001012975-25-000083 ↗ filed Feb 13, 2025
Holdings Value
Holdings 35 stocks · $116.9M
| ILMN Illumina Inc. | 13.62% | 119,196 | $15.9M | No change |
| HRMY Harmony Biosciences Holdings | 10.85% | 368,665 | $12.7M | No change |
| OCS Oculis Holding AG | 6.34% | 436,378 | $7.4M | No change |
| VRNA Verona Pharma Ltd. | 5.28% | 133,040 | $6.2M | New |
| ZLAB Zai Lab Ltd.-ADR | 5.26% | 235,000 | $6.2M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 4.43% | 125,330 | $5.2M | Add +18.1% |
| MRUS Merus NV | 4.32% | 120,038 | $5.0M | No change |
| GERN Geron Corp. | 4.16% | 1,373,550 | $4.9M | No change |
| INCY Incyte Corp. | 3.96% | 67,022 | $4.6M | Reduce -9.5% |
| RXRX Recursion Pharmaceuticals-A | 3.84% | 664,610 | $4.5M | New |
| XENE Xenon Pharmaceuticals Inc. | 3.58% | 106,680 | $4.2M | No change |
| REPL Replimune Group Inc. | 3.33% | 321,746 | $3.9M | Add +11.8% |
| TRML Tourmaline Bio Inc. | 3.25% | 187,090 | $3.8M | Add +27.4% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 3.16% | 19,997 | $3.7M | Reduce -13.1% |
| SLNO Soleno Therapeutics Inc. | 3.06% | 79,650 | $3.6M | Add +24.6% |
| MDGL Madrigal Pharmaceuticals Inc. | 2.94% | 11,122 | $3.4M | Add +13.9% |
| LAB Standard Biotools Inc. | 2.82% | 1,883,179 | $3.3M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 2.35% | 49,120 | $2.7M | No change |
| EXEL Exelixis Inc. | 1.83% | 64,200 | $2.1M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 1.62% | 102,984 | $1.9M | No change |
| ASND Ascendis Pharma A/S | 1.60% | 13,600 | $1.9M | No change |
| RBRK Rubrik Inc. Class A | 1.36% | 24,338 | $1.6M | New |
| KALV Kalvista Pharmaceuticals Inc. | 1.12% | 154,522 | $1.3M | No change |
| KYMR Kymera Therapeutics Inc. | 1.06% | 30,875 | $1.2M | Add +183.9% |
| BCYC Bicycle Therapeutics PLC-ADR | 0.83% | 68,943 | $965K | Add +118.3% |
| TRDA Entrada Therapeutics Inc. | 0.73% | 49,082 | $849K | No change |
| RVMD Revolution Medicines Inc. | 0.72% | 19,253 | $842K | Add +163.7% |
| CLYM Climb Bio Inc. | 0.71% | 463,654 | $835K | No change |
| RANI Rani Therapeutics Holdings Class A | 0.58% | 493,584 | $676K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.53% | 1,166,952 | $624K | No change |
| BOLT PROJS HLDGS INC | 0.33% | 811,952 | $391K | No change |
| ARGX Argenx SE - ADR | 0.23% | 430 | $264K | No change |
| DBVT DBV Technologies SA-Spon ADR | 0.10% | 37,095 | $115K | No change |
| ALXO Alx Oncology Holdings Inc. | 0.06% | 41,950 | $70K | No change |
| AFMDQ Affimed NV | 0.04% | 37,247 | $44K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| LBPH Longboard Pharmaceuticals Inc. | Sold out | 0.00% | −4.61 |
| EXAI Exscientia Ltd. | Sold out | 0.00% | −3.62 |
| ONC Beone Medicines Ltd.-ADR | Reduce -13.1% | 3.16% | −1.29 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −0.65 |
| INCY Incyte Corp. | Reduce -9.5% | 3.96% | −0.26 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −0.21 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.18 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.09 |
Portfolio Buys Q3 2024 → Q4 2024
| VRNA Verona Pharma Ltd. | New | 5.28% | +5.28 |
| RXRX Recursion Pharmaceuticals-A | New | 3.84% | +3.84 |
| RBRK Rubrik Inc. Class A | New | 1.36% | +1.36 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +13.9% | 2.94% | +1.15 |
| MIRM Mirum Pharmaceuticals Inc. | Add +18.1% | 4.43% | +0.87 |
| KYMR Kymera Therapeutics Inc. | Add +183.9% | 1.06% | +0.62 |
| REPL Replimune Group Inc. | Add +11.8% | 3.33% | +0.61 |
| RVMD Revolution Medicines Inc. | Add +163.7% | 0.72% | +0.43 |
| SLNO Soleno Therapeutics Inc. | Add +24.6% | 3.06% | +0.28 |
| BCYC Bicycle Therapeutics PLC-ADR | Add +118.3% | 0.83% | +0.21 |
| TRML Tourmaline Bio Inc. | Add +27.4% | 3.25% | −0.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |